Clinical trials: Obesity, Prediabetes
Type 2 Diabetes
Quantitative 18F-AV-133 PET Imaging in Subjects With Diabetes and Healthy Controls
To evaluate 18F-AV-133 imaging of the pancreas in patients with early type 2 diabetes, late type 2 diabetes, subjects with pre-diabetes and in healthy overweight/obese control subjects.
- Trial name
- NCT01710371
- Testing
- 18F-AV-133, 10% Arginine Hydrochloride-R-Gene 10
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Obesity
Research Study Looking at How Well Semaglutide Works in People Living With Obesity and Prediabetes
This study looks at how well a new medicine, called semaglutide, works at helping people with obesity and prediabetes. This study will look at how much weight participants lose, and if participants can go from having blood sugar…
- Trial name
- STEP 10 (NCT05040971)
- Testing
- Semaglutide 2.4 mg
- Where
- 43 sites in Canada, Denmark and 3 more
- Volunteers
- 207 people
- Sponsor
- Novo Nordisk A/S
PreDiabetes, Pre Diabetes
STAR Study Investigating Performance and Safety of the Medical Device SiPore15™
The primary objective of STAR01 is to evaluate the performance and safety of the medical device (class IIb) SiPore15™ after a 12-week long treatment in the target population of obese and overweight subjects with prediabetes or…
- Conditions
- PreDiabetes, Pre Diabetes, Prediabetic State, Type2 Diabetes
- Trial name
- NCT03823027
- Testing
- SiPore15™
- Where
- 2 sites in Finland, Sweden
- Volunteers
- 43 people
- Sponsor
- Sigrid Therapeutics AB
Obesity & Overweight, Circadian Rhythm Disorders
Effects of Akkermansia Muciniphila and Berberine Supplementation on Insulin Sensitivity in Night-shift Workers
Night shift work is associated with an increased risk of obesity, insulin resistance, and cardiometabolic disorders, largely due to circadian misalignment, disrupted sleep, and altered eating patterns.
- Conditions
- Obesity & Overweight, Circadian Rhythm Disorders, Gut Microbiota Modulation, Prediabetes (Insulin Resistance, Impaired Glucose Tolerance)
- Trial name
- Shift2Health (NCT07440147)
- Testing
- Verum (A)
- Where
- Austria
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- FH Joanneum Gesellschaft mbH
Prediabetes, Type 2 Diabetes
Effect of Totum-63, Active Ingredient of Valedia, on Glucose and Lipid Homeostasis on Subjects With Prediabetes
Given the data on the active ingredients of Totum-63, this research aims to evaluate the effect of its chronic consumption (24 weeks) on glucose and lipid homeostasis and especially on fasting plasma glucose in volunteers with…
- Conditions
- Prediabetes, Type 2 Diabetes, Hypertriglyceridemia, Obesity
- Trial name
- TOTUM-63 TWO (NCT02868177)
- Testing
- Totum-63
- Where
- 6 sites in France, Ireland and 2 more
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Valbiotis
Overweight and Obesity
The Effect of Extended Use of the EPITOMEE CAPSULE (ELECT)
The Effect of Extended Use of the Epitomee Capsule on BodyWeight in subjects with Overweight and Obesity with and without Prediabetes
- Trial name
- NCT04994769
- Testing
- Epitomee Capsule
- Where
- 3 sites in United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Epitomee medical
Insulin Resistance, Abdominal Obesity
Pilot Study With GFT505 (80mg) in Patients With Insulin Resistance and Abdominal Obesity
The purpose of this study is to demonstrate the efficacy on insulin sensitivity of GFT505 at 80mg/d in male patients with insulin resistance and abdominal obesity. Evaluation will be made using a glucose clamp technique.
- Trial name
- NCT01271777
- Testing
- GFT505 80mg
- Where
- 2 sites in France
- Volunteers
- 22 people
- Sponsor
- Genfit
Impaired Glucose Tolerance, Abdominal Obesity
Pilot Study With GFT505 (80mg) in Patients Presenting With Impaired Glucose Tolerance and Abdominal Obesity.
The purpose of this study is to evaluate the efficacy of GFT505 80mg compared with placebo in improving Oral Glucose Tolerance Test (OGTT), in patients with impaired glucose tolerance and abdominal obesity, and to assess the…
- Trial name
- NCT01275469
- Testing
- GFT505 80mg
- Where
- 20 sites in France
- Volunteers
- 47 people
- Sponsor
- Genfit
Weight Loss, Metabolic Syndrome
Use of Continuous Glucose Monitoring in Non-Diabetic Population to Compliment Signos Mobile Health Platform
Metabolic syndrome and resulting downstream health effects remains a growing health concern. In published trials, the use of continuous glucose monitoring (CGM) assists behavioral changes efforts, leading to improved adherence…
- Conditions
- Weight Loss, Metabolic Syndrome, Pre-diabetes, Central Obesity
- Trial name
- NCT05121844
- Testing
- Continuous Glucose Monitor Device
- Where
- United States
- Volunteers
- 31,187 people, healthy volunteers welcome
- Sponsor
- Signos Inc
Chronic Disease, Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Truway Diagnostic Tools in Primary Care
This study evaluates the effectiveness of Truway Health-sourced portable diagnostic devices, including ultrasound and blood glucose monitors, in early detection of chronic conditions in outpatient primary care settings.
- Conditions
- Chronic Disease, Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight, Hypertension, Cardiovascular Disease Acute
- Trial name
- TruDxPC (NCT07209527)
- Testing
- Truway Portable Ultrasound Device, Truway Blood Glucose Monitor, Standard Oral Hypoglycemic Agent
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Truway Health, Inc.
Overweight, Prediabetic State
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
This study will evaluate the efficacy and safety of orforglipron in participants with overweight and assess whether it helps reduce the future risk of obesity-related conditions, including type 2 diabetes, hypertension, and…
- Conditions
- Overweight, Prediabetic State, Prehypertension, Obesity, Abdominal
- Trial name
- ATTAIN-NOW (NCT07794579)
- Testing
- Orforglipron
- Where
- 180 sites in United States, Argentina and 10 more
- Volunteers
- 2,001 people
- Sponsor
- Eli Lilly and Company
Overweight and Obesity
The Effect of Epitomee Capsule on Body Weight in Patients With Overweight and Obesity
The effect of Epitomee Capsule on body weight in patients with overweight and obesity with and without Prediabetes
- Trial name
- RESET (NCT04222322)
- Testing
- Epitomee Capsule
- Where
- 9 sites in United States
- Volunteers
- 279 people, healthy volunteers welcome
- Sponsor
- Epitomee medical
Obesity, Obesity, Abdominal
Vestibular Stimulation to Trigger Adipose Loss Clinical Trial
There is an ongoing and worsening problem with obesity in the developed, and much of the developing world. Although it has long been realized that Western diets that are rich in sugar and fat play an important role in this, it…
- Conditions
- Obesity, Obesity, Abdominal, Metabolic Syndrome, Weight Loss
- Trial name
- VeSTAL (NCT03138369)
- Testing
- Vestibular nerve stimulator
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Neurovalens Ltd.
Metabolic Syndrome
A Study to Explore the PK and PD of INV-202 in Metabolic Syndrome
INV-202-CL-105 is a phase 1B study to examine the safety and tolerability, as well as the pharmacokinetics (PK) pharmacodynamic (PD) effects of INV-202 in subjects with metabolic syndrome over 28 days.
- Trial name
- NCT05282446
- Testing
- INV-202
- Where
- Canada
- Volunteers
- 37 people
- Sponsor
- Inversago Pharma Inc.
Obesity
Weight Loss in Pre-diabetic, Obese Women
This is a six (6) month, single center, randomized, double-blind, parallel, controlled-feeding weight-loss study comparing two dietary groups (triglyceride and olestra) in pre-diabetic obese women.
- Trial name
- NCT00686816
- Testing
- Low calorie diet, Olestra
- Where
- Russia
- Volunteers
- 80 people
- Sponsor
- Procter and Gamble
Type 2 Diabetes, Obese
The Effects of the GOLO for Life® Plan With Release Supplement on Glycemic Control and Weight in Overweight and Obese Adults With Prediabetes or Type 2 Diabetes
The objective of this study is to investigate the efficacy and safety of the GOLO for Life® Plan (G4LP) and Release supplementation on glycemic control and weight in overweight and obese adults with Prediabetes or Type 2…
- Conditions
- Type 2 Diabetes, Obese, Overweight, Prediabetes
- Trial name
- NCT05844644
- Testing
- Release
- Where
- 2 sites in Canada
- Volunteers
- 100 people
- Sponsor
- Golo
Overweight, Diabetes
Effect of Gelesis200 on Body Weight in Overweight and Obese Subjects w/o Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Assessing the Effect of Gelesis200 on Body Weight in Overweight and Obese Subjects without or with Type 2 Diabetes
- Conditions
- Overweight, Diabetes, PreDiabetes, Obesity
- Trial name
- LIGHT-UP (NCT03058029)
- Testing
- Gelesis200
- Where
- 30 sites in United States, Canada and 6 more
- Volunteers
- 300 people
- Sponsor
- Gelesis, Inc.
Prediabetes, Overweight
Evaluation of Prevent in Underserved Populations
The goal of this study is to evaluate an online Diabetes Prevention Program adapted for patients with prediabetes in safety net health care settings.
- Conditions
- Prediabetes, Overweight, Obesity
- Trial name
- PUP (NCT02664064)
- Testing
- Prevent
- Where
- 3 sites in United States
- Volunteers
- 227 people, healthy volunteers welcome
- Sponsor
- Omada Health, Inc.
Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities, Overweight (BMI > 25)
AIM-WEIGHT: AI-Guided Microbiome-Targeted Nutritional Intervention for Weight Loss
AIM-WEIGHT is a clinical study evaluating whether a fixed microbiome-targeted nutritional supplement can support weight loss in adults with overweight or obesity who do not have prediabetes or diabetes.
- Trial name
- AIM-WEIGHT (NCT07736547)
- Testing
- AI-Guided Microbiome-Targeted Nutritional Supplement, Lifestyle counselling
- Where
- Turkey (Türkiye)
- Volunteers
- 80 people
- Sponsor
- Varol TUNALI
Metabolism and Nutrition Disorder, Obesity
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes
This trial is conducted in Africa, Asia, Europe, Oceania, North America and South America. The aim of this clinical trial is to evaluate the potential of liraglutide to induce and maintain weight loss over 56 weeks in obese…
- Trial name
- NCT01272219
- Testing
- liraglutide
- Where
- 226 sites in United States, Argentina and 27 more
- Volunteers
- 3,731 people
- Sponsor
- Novo Nordisk A/S